Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets

Presented herein is the case of a heavily pretreated patient with high‐grade neuroendocrine prostate cancer that achieved a complete metabolic response on platinum‐based chemotherapy after treatment with the dual CD‐47 and SIRP‐α inhibitor, RRx‐001, in a Phase II clinical trial.

Detalles Bibliográficos
Autores principales: Ojemuyiwa, Michelle, Zeman, Karen, Spira, Alexander, Oronsky, Bryan, Ray, Carolyn, Trepel, Jane B., Lee, Min‐Jung, Onyiuke, Ifeyinwa, Brzezniak, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293266/
https://www.ncbi.nlm.nih.gov/pubmed/30564353
http://dx.doi.org/10.1002/ccr3.1880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293266/
https://www.ncbi.nlm.nih.gov/pubmed/30564353
http://dx.doi.org/10.1002/ccr3.1880

Ejemplares similares